Bibliography
- Inoue A , SaijoY, MaemondoM et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361(9373) , 137–139 (2003).
- Takano T , OheY, KusumotoM et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1) , 93–104 (2004).
- American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med.165(2) , 277–304 (2002).
- Abid SH , MalhotraV, PerryMC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr. Opin. Oncol.13(4) , 242–248 (2001).
- Raghu G , NybergF, MorganG.The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer91(Suppl. 2) , S3–S10 (2004).
- Kudoh S , KatoH, NishiwakiY et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case–control study. Am. J. Respir. Crit. Care Med. 177(12) , 1348–1357 (2008).
- Storey JD , TibshiraniR. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA100(16) , 9440–9445 (2003).
- Wijnen PA , DrentM, NelemansPJ et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case–control study in The Netherlands. Drug Saf. 31(12) , 1125–1134 (2008).
- Ando M , OkamotoI, YamamotoN et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 24(16) , 2549–2556 (2006).
▪ Website
- Clinicaltrials.gov. Iressa case–control study in Japan http://clinicaltrials.gov/ct2/show/NCT00252759